JPWO2021252054A5

JPWO2021252054A5 -

Info

Publication number: JPWO2021252054A5
Application number: JP2022575897A
Authority: JP
Publication date: 2024-04-16

Claims

1. A pharmaceutical composition for use in a method of treating an ophthalmic condition of the eye, the method comprising administering the pharmaceutical composition to, within or about the eye via a delivery device and according to a predetermined dosing regimen ;
The pharmaceutical composition does not contain a preservative;
The pharmaceutical composition comprises:
(1) Prednisolone _PO4 about 1%, Moxifloxacin HCl about 0.5%, and Bromfenac about 0.075%,
(2) Prednisolone _PO4 about 1% and moxifloxacin HCl about 0.5%;
(3) about 0.5% moxifloxacin HCl and about 0.075% bromfenac;
(4) about 0.05% difluprednate, about 0.5% moxifloxacin HCl, and about 0.075 % bromfenac
one of
These percentages are in terms of weight per volume, and said ophthalmic condition is post-cataract surgery care, post-LASIK surgery care, eye retina care after cataract surgery, eye retina care after retinal surgery, conditions in preparation for intraocular surgery, or conditions during intraocular surgery.

The pharmaceutical composition of claim 1 , wherein the delivery device is an eye dropper.

The pharmaceutical composition of claim 2 , wherein the eye dropper is a multi-dose eye dropper.

4. The pharmaceutical composition of claim 3, wherein the multi-dose eye dropper is (i) a dropper bottle for dispensing predetermined metered amounts of liquid, the dropper bottle having a check position that prevents the liquid from flowing back into the dropper bottle, or (ii) an ophthalmic squeeze dispenser (OSD) including a sealing closure member that closes the dispenser opening when liquid present near the dispenser opening is at a pressure below a predetermined threshold.

2. The pharmaceutical composition of claim 1, wherein the predetermined dosing regimen is once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once per month .

2. The pharmaceutical composition of claim 1, comprising about 1% prednisolone _PO4 , about 0.5% moxifloxacin HCl, and about 0.075% bromfenac.

1. A pharmaceutical composition for use in a method of treating an ophthalmic condition of the eye, the method comprising administering the pharmaceutical composition via a delivery device and to, within, or around the eye according to a predetermined dosing regimen, the pharmaceutical composition comprising at least two active pharmaceutical ingredients that are combined and stored in communication with one another, the pharmaceutical composition does not comprise a preservative, the method is more effective compared to existing methods, the existing methods administering the at least two active pharmaceutical ingredients from at least two separate and distinct containers, and the pharmaceutical composition comprising:
(1) Prednisolone PO _４4 about 1%, moxifloxacin HCl about 0.5%, and bromfenac about 0.075%,
(2) Prednisolone PO _４4 about 1%, and moxifloxacin HCl about 0.5%,
(3) about 0.5% moxifloxacin HCl and about 0.075% bromfenac;
(4) about 0.05% difluprednate, about 0.5% moxifloxacin HCl, and about 0.075% bromfenac
one of
These percentages relate to weight per volume of the pharmaceutical composition.

8. The pharmaceutical composition of claim 7, wherein the ophthalmic condition is one or more of post-cataract surgery care, post-LASIK surgery care, retina of the eye care after cataract surgery, retina of the eye care after retinal surgery, conditions in preparation for intraocular surgery, or conditions during intraocular surgery.

The pharmaceutical composition of claim 7 , wherein the delivery device is an eye dropper.

10. The pharmaceutical composition of claim 9, wherein the eye dropper is a multi-dose eye dropper.

11. The pharmaceutical composition of claim 10, wherein the multi-dose eye dropper is (i) a dropper bottle for dispensing predetermined metered amounts of liquid, the dropper bottle having a check position that prevents the liquid from flowing back into the dropper bottle, or (ii) an ophthalmic squeeze dispenser (OSD) including a sealing closure member that closes the dispenser opening when liquid present near the dispenser opening is at a pressure below a predetermined threshold.

8. The pharmaceutical composition of claim 7, wherein the predetermined dosing regimen is once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once per month.

The pharmaceutical composition comprises prednisolone PO _４4 8. The pharmaceutical composition of claim 7, comprising about 1%, moxifloxacin HCl about 0.5%, and bromfenac about 0.075%.